# AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

> **NCT03253679** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm

## Interventions

- **DRUG:** Adavosertib

## Key facts

- **NCT ID:** NCT03253679
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253679, "AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03253679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*